Silencing in Medical Technology

Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach

... and IL-12) and induce RNAi-mediated gene silencing as demonstrated by the selective inhibition of ... and do act by selectively silencing the specifically targeted gene. We believe by ... Synthetic siRNA Mediating Potent Gene silencing in Vivo." Notes to Editors: About Silence ...

Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research

... faced when using RNAi, leading to permanent gene silencing in a wide range of cell types. "With the ... can now effectively deliver stably expressed gene silencing sequences into a broad range of cell ... algorithm uses criteria unique to shRNA- based silencing for the routine production of highly ...

Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinson's Disease Under Rapid Response Innovation Awards 2008

... expected by year's end NEW YORK, July 29 /PRNewswire-USNewswire/ -- Gene silencing techniques and induced pluripotent stem cell technology are among the ... MD, PhD, of Columbia University is working to determine whether a gene silencing technique using microRNAs -- short, noncoding molecules of RNA -- can be ...

Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology

... Dharmacon Accell siRNA achieves highly efficient siRNA delivery for gene silencing without the need for optimization," explained Jardine. "In addition, the ... of RNAi experiments." Preliminary studies also suggest that long-term silencing of up to 30 days can now be achieved through repeated application of ...

Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD

... because it is the first-ever Phase 3 trial of an agent based on RNAi gene silencing technology and because the growing population of older people at risk of ... healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase 3 trial after successfully ...

Benitec MOU With CalbaTech, Inc.

... a license agreement with Benitec, an Australian corporation. Gene silencing Gene silencing is about controlling the flow of genetic information. Our genome operates ...

Alfacell Provides Shareholder Update

... of the clinical and regulatory arena. One such experiment we are looking into is whether Onconase can be used as routine tool to detect the gene silencing via RNA interference (RNAi) mechanism. Currently, there are thousands of researchers interested in finding the answer about the RNAi-mediated gene ...

Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs

... embryos. In striking contrast, the human-animal hybrids showed no difference or a down-regulation of these critical pluripotency genes effectively silencing them--thus making the generation of stem cells impossible. Without appropriate reprogramming, these data call into question the potential use of ...

Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye

... 14, May 28, 2008 About OPKO Health, Inc. Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III trial after successfully completing Phase II trials for wet age-related macular degeneration and ...

Presentation of Data on Progen's Cancer Epigenetic Targets Platform

... itself, but rather are associated with changes in the activation and regulation of gene transcription. Its role in cancer, through the aberrant silencing or repression of gene expression, is now recognized and a number of epigenetic targets in oncology have now been identified. LSD-1 is the first ...

Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008

... host cells without adverse effects, and eliminated by the body through its own natural processes. This method has been shown to induce targeted gene silencing (in other words, it disables the "bad" gene or genes that cause disease, without affecting the surrounding genes), delivering significant therapeutic ...

OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection

... About OPKO Health, Inc. Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III trial after successfully completing Phase II trials for wet age-related macular degeneration and ...

UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies

... Park: Flexible and High Performance Biometric Tools; $121,505. -- Gaithersburg-based Sirnaomics, Inc. and the University of Maryland, Baltimore: silencing Scar Formation by Targeting Hoxb13: $158,199. -- Silver Spring-based Technologies and Devices International Inc. and the University of Maryland, ...

Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics

... involving gross pathologic hallmarks such as stage and grade are now being further augmented by data detailing the overexpression of oncogenes, silencing of tumor suppressors and presence of mutant forms of relevant markers. In each of these cases novel targeted agents and various combination ...

Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

... gene expression. Epigenetic changes can silence gene expression and, unlike DNA mutations, may be reversed by targeting the mechanisms involved. The silencing of key cell cycle control genes and tumor suppressor genes through these two mechanisms of epigenetic regulation has been demonstrated in vitro and ...

MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule

... of gene expression. Epigenetic changes can silence gene expression and, unlike DNA mutations, may be reversed by targeting the enzymes involved. The silencing of key cell cycle control genes and tumor suppressor genes through these two mechanisms of epigenetic regulation has been demonstrated in vitro and ...

Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice

... capable of delivering vascular endothelial growth factor (VEGF) targeted small interfering RNAs (siRNAs) that suppress tumor-induced angiogenesis by silencing target gene expression in mice. The study findings support the preclinical development of ICS-283 a nanoparticle-based compound comprised of siRNAs ...

Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules

... relates to new classes of chemically modified siRNA structures that have been tested in cell culture and have demonstrated enhanced stability, silencing activity, and cell penetration. Several new molecules are currently in preclinical testing. This research is part of Quark's program to develop novel ...

Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)

... gene expression. Epigenetic changes can silence gene expression and, unlike DNA mutations, may be reversed by targeting the mechanisms involved. The silencing of key cell cycle control genes and tumor suppressor genes through these two mechanisms of epigenetic regulation has been demonstrated in vitro and ...

Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer

... of a VEGF-specific siRNA in a rodent model; -- silencing of KSP mRNA in vivo by greater than 50 ... of siRNAs to cells of the liver and efficient silencing of genes expressed in that organ. Liposomal ... occurring mechanism within cells for selectively silencing and regulating specific genes. The discovery of ...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

... DNA mutations, may be reversed by targeting the enzymes involved. The silencing of key cell cycle control genes and tumor suppressor genes through these ... DNA mutations, may be reversed by targeting the enzymes involved. The silencing of key cell cycle control genes and tumor suppressor genes through ...

Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal

... at http://www.pnas.org. About RNA Interference (RNAi) RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes ...

Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity

... of these diseases. About RNA Interference (RNAi) RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. The discovery of RNAi has been widely acknowledged as a major breakthrough in biology, and the technology was ...

Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

... in patients. About RNA Interference (RNAi) RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes ...

Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

... a journal published by the American Association of Cancer Research (AACR). This paper describes how Calando's proprietary siRNA duplex demonstrated silencing of the target gene, RRM2, and reduced cell proliferation across multiple species and cancer types, both in cell culture and in whole animals. These ...

Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the American Association of Cancer Research Annual Meeting in Los Angeles

... and deposit mediators of RNA interference (short hairpin RNA) directly into the target cells. This method, which has been shown to induce gene silencing and therapeutic effects in multiple model systems, including live animals, forms the basis for Cequent's pipeline of clinical drug candidates. ...

Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus

... infected with RSV. About RNA Interference (RNAi) RNA interference (or RNAi) is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. The discovery of RNAi has been widely acknowledged as a major breakthrough in biology, and the technology was ...

Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting

... to silence key tumor suppressor genes in cancer, we are able to choose epigenetic drugs from within our portfolio to combine and attack these silencing systems simultaneously, with encouraging clinical data emerging in the context of acute myeloid leukemia." Pharmion has three epigenetic products ...

Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study

... 1. Stupp et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996. 2. Hegi et al., MGMT gene silencing and benefit from temozolomide in glioblastoma. NEJM 2005; 352(10):997-1003. 3. Max Parkin et al. Global Cancer Statistics, 2002. CA Cancer J Clin ...

Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia

... LNA drugs, with their high potency and biostability, have the potential to transform the field of RNAi medicines, making specific and effective gene silencing a reality in human medicine. If this potential is realised, even in part, it may be possible to design new drugs to treat the underlying ...